enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

Core Insights - enGene Holdings Inc. (NASDAQ: ENGN) has shown promising early data, leading to a "Strong Buy" sentiment from analysts [1] Company Analysis - The company is involved in the biotech sector, focusing on clinical trials and innovative therapies [1] - The analyst has a PhD in biochemistry and extensive experience in analyzing biotech companies, indicating a strong foundation for evaluating enGene's potential [1] Industry Context - The biotech industry is characterized by high volatility and significant investment risks, necessitating thorough due diligence by investors [1]